US Pharm. 2010;35(11)(Oncology suppl):17.
Peregrine Pharmaceuticals, Inc., reported interim data at the 2010 Congress of Neurological Surgeons Annual Meeting from an ongoing phase II clinical trial of its novel brain cancer therapy, Cotara. Interim median overall survival in the trial was 86 weeks for a cohort of 14 patients with glioblastoma multiforme treated at first relapse with a single infusion of Cotara, a targeted monoclonal antibody linked to a radioisotope that destroys the tumor from the inside out with minimal exposure to healthy tissue.
"Interim survival data from patients treated with Cotara have been encouraging, previously ranging from 38 to 41 weeks, when expected survival for these patients is typically 24 weeks from time of disease recurrence," said Joseph S. Shan, MPH, vice president, clinical and regulatory affairs, Peregrine Pharmaceuticals.
